Literature DB >> 7997334

Vascular targeting in photodynamic occlusion of subretinal vessels.

U Schmidt-Erfurth1, T Hasan, E Gragoudas, N Michaud, T J Flotte, R Birngruber.   

Abstract

PURPOSE: To evaluate the potential of photodynamic therapy (PDT) using benzoporphyrin derivative (BPD) for occlusion of subretinal neovascular membranes, the authors studied efficiency and collateral damage of PDT-induced photothrombosis in the rabbit choriocapillary layer.
METHOD: Benzoporphyrin derivative, a new photosensitizer, currently in clinical trials for tumor therapy, was used. Low-density lipoprotein served as a carrier to enhance selective targeting of vascular endothelial cells.
RESULTS: Complete choriocapillary occlusion was achieved at a BPD dose of 2 mg/kg and a radiant exposure as low as 10 J/cm2. When PDT was performed 3 hours after BPD application, damage to the neural retina was minimal. Only inner photoreceptor segments showed mitochondrial swelling probably secondary to choroidal ischemia. Bruch's membrane remained intact. Retinal pigment epithelium was invariably damaged as seen with other photosensitizers.
CONCLUSION: Compared with photocoagulation BPD-PDT allows endothelial-bound intraluminal photothrombosis, sparing important structures such as neural retina and Bruch's membrane. It may thus provide a more selective treatment of juxtafoveal and subfoveal neovascular membranes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7997334     DOI: 10.1016/s0161-6420(13)31079-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  37 in total

1.  Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy.

Authors:  Yan Baglo; Aaron J Sorrin; Barry J Liang; Huang-Chiao Huang
Journal:  Photochem Photobiol       Date:  2020-02-16       Impact factor: 3.421

2.  Choroidal thickness outside the laser irradiation area after photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Yukinori Sugano; Tomohiro Iida; Ichiro Maruko; Akira Ojima; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2013-02-14       Impact factor: 2.447

3.  Predictors and Limitations of the Penetration Depth of Photodynamic Effects in the Rodent Brain.

Authors:  Collin T Inglut; Brandon Gaitan; Daniel Najafali; Irati Abad Lopez; Nina P Connolly; Seppo Orsila; Robert Perttilä; Graeme F Woodworth; Yu Chen; Huang-Chiao Huang
Journal:  Photochem Photobiol       Date:  2019-10-13       Impact factor: 3.421

4.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

5.  Concentric retinal pigment epithelium atrophy after a single photodynamic therapy.

Authors:  Joachim Wachtlin; Tim Behme; Heinrich Heimann; Ulrich Kellner; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-05-07       Impact factor: 3.117

6.  [Transient visual decrease after photodynamic therapy].

Authors:  S Mennel; N Hausmann; C H Meyer; S Hörle; S Peter
Journal:  Ophthalmologe       Date:  2005-01       Impact factor: 1.059

7.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

8.  Verteporfin photodynamic therapy of retinal capillary hemangioblastoma in von Hippel-Lindau disease.

Authors:  Harsha Bhattacharjee; Hemalata Deka; Satyen Deka; Manab Jyoti Barman; Mrinal Mazumdar; Jnanankar Medhi
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

9.  Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.

Authors:  Eric Chen; David M Brown; Tien P Wong; Matthew S Benz; Eric Kegley; Joel Cox; Richard H Fish; Rosa Y Kim
Journal:  Clin Ophthalmol       Date:  2010-10-05

10.  Visual hallucinations and Charles Bonnet syndrome after photodynamic therapy for age related macular degeneration.

Authors:  S Y Cohen; A Bulik; R Tadayoni; G Quentel
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.